[PIPA] Contract synthesis of pyrrole-imidazole polyamide / reagent sales

basic information

Outstanding Features of Competing Technologies and PIPA Nucleic acid drugs are being developed, but they are easily degraded in vivo and have not been put to practical use. PIPA remains stable in vivo without being degraded by nucleic acid-degrading enzymes. Peptide nucleic acids (PNA) have attracted attention as gene therapy drugs, but they have not yet been realized due to issues such as cellular uptake and toxicity. siRNA is known as a method to suppress gene expression, but it poses problems due to side effects caused by the activation of Toll-like receptors. By specifically designing PIPA to target the promoter sequences of target genes, it is possible to suppress only the transcription of the target gene. - TGF-b1: A protein involved in progressive renal impairment, liver cirrhosis, pulmonary fibrosis, vascular stenosis, skin scarring, keratitis, cancer metastasis, etc. - Lox-1: A protein involved in atherosclerosis. - CTGF: A protein involved in angiogenesis, cell migration, and bone formation. - TMPRSS2-ERG: A protein involved in prostate cancer, influencing cell carcinogenesis and the progression of cancer malignancy.

Price information

Please contact us.

Delivery Time

※Please contact us.

Applications/Examples of results

Polyamide (PIPA) composed of pyrrole and imidazole is a low molecular weight organic compound discovered from antibiotics, which binds to double-stranded DNA in a sequence-specific manner more strongly than transcription factors, and powerfully suppresses the transcriptional activity of target genes (refer to literature). It is resistant to nucleases and stable in vivo, and is known to be taken up into the cell nucleus without vectors or delivery reagents. At HiPep Research Institute, we are engaged in the contract synthesis of PIPA with molecular design through chemical synthesis. PIPA is expected to be a novel gene transcription control drug for intractable diseases for which effective treatments are still unavailable. *Please contact us if you have requests for labeling, derivatization, or design of related sequences.

Line up（9）